A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1.

摘要

S-l is a recently developed oral fluoropyrimidine-based antineoplastic agent consisting of the fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate.1 S-l is more active and less toxic than intravenous 5-FU, with fewer gastrointestinal side effects. S-l is usually administered as capsules taken twice a day. Ito et al.2 were the first in Japan to report a case of corneal epithelial lesion due to S-l. However, to our knowledge, there have been no reports so far on pigmentation, particularly melanokeratosis, appearing in the cornea and conjunctiva as a result of S-l treatment. We present a case in which a corneal epithelial lesion and kera-toconjunctival pigmentation developed after oral administration of S-l, necessitating regular follow-up to avoid irreversible visual loss.